Lapatinib Plus Trastuzumab Was Not Superior to Trastuzumab Alone or Trastuzumab Followed by Lapatinib for Improved DFS in Women with HER2+ Breast Cancer

This article presents results of the global, Phase 3, randomized Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study; BIG 2–06/N063D [ALTTO; NCT00490139], conducted with more than 8300 women with human epidermal growth factor receptor 2-positive (HER2+) breast cancer. This study evaluated concurrent or sequential adjuvant lapatinib plus trastuzumab. Although the combination is safe, the primary endpoint of improved disease-free survival was not met.